CTLA4 and melanoma: Moreover, an increased effector CD8+ T-cell:Treg ratio within the tumour infiltrating lymphocyte (TIL) population has been shown to be a crucial predictor of anti-CTLA-4’s clinical efficacy in melanoma patients [14].